Expanding the Use of Naloxone to Treat Opioid Overdose

Activity Preview

Pharmacists who are well informed about the use and regulatory framework for naloxone can help address barriers to naloxone access and reduce the public health burden of opioid overdose.

 

 
Learning Objectives

After participating in this activity, the pharmacist will be able to: 

  1. Explain the mechanism of action of 
naloxone in the management of opioid 
overdose. 

  2. Discuss how to educate patients and 
their caregivers to identify signs and 
symptoms of opioid overdose. 

  3. Identify information that should be 
included in patient education on admin- 
istration of various forms of naloxone. 

  4. State the current regulatory status of 
naloxone and approaches to providing 
access. 

  5. List barriers to wider distribution of 
naloxone, and describe strategies to overcome these barriers. 


Activity type: Knowledge-based

Learning Level: 2

 

Accreditation Information

ACPE logo

The American Pharmacists Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

To obtain 2.0 contact hours of continuing pharmacy education credit (0.2 CEUs) for completing " Expanding the Use of Naloxone to Treat Opioid Overdose," complete the CPE examination and evaluation questions. Credit will be awarded upon achieving a passing grade of 70% or better. Please visit CPE Monitor for your statement of credit/transcript.

APhA continuing pharmacy education policy provides you with two opportunities to successfully complete this continuing pharmacy education examination. Please note that you will not be permitted to submit the examination a third time. Exam questions may not appear in the same order as printed.

The current policy of the APhA Education Department is not to release the correct answers to any of our CPE tests. This policy is intended to maintain the integrity of the CPE activity and the test. Individuals completing this activity by February 1, 2019 can receive credit.

Initial release date: February 1, 2016
Expiration date: February 1, 2019

ACPE Universal Activity Number: 0202-0000-16-087-H01-P

 

Advisory Board

Jeffrey Fudin, PharmD, DAAPM, FCCP, FASHP
Clinical Pharmacy Specialist in Pain Management
Director, Postgraduate Year 2 Pain & Palliative Care Pharmacy Residency Programs
Samuel S. Stratton VA Medical Center
Albany, NY

 

Disclosures

Jeffrey Fudin, PharmD, DAAPM, FCCP, FASHP discloses that he has been a speaker for AstraZeneca, Kaléo Pharma, and Millennium Health; on the advisory board for AstraZeneca, Depomed, and Kaléo Pharma; a consultant for Endo Pharmaceuticals, KemPharm, and Scilex Pharmaceuticals; and owner of Remitigate, LLC. Fudin’s participation and opinions are his own and do not reflect those of any pharmaceutical companies listed, nor was it prepared as part of his official gov- ernment duties. For complete staff disclosures, please see the APhA Accreditation Information section at www.pharmacist.com/education.

 

Development

"Expanding the Use of Naloxone to Treat Opioid Overdose” is a home-study continuing education activity for pharmacists developed by the American Pharmacists Association.

 

Activity Fee

There is no fee associated with this activity for members of the American Pharmacists Association. There is a $25 fee for nonmembers.

Credit Information

Activity Number Credit Amount Accreditation Period
ACPE# 0202-0000-16-087-H01-P 0.2 CEUs February 01, 2016 - February 01, 2019